Latest Sales And Development News

NuEnergy Gas Limited has announced a $4.62 million entitlement offer, primarily to fund early gas sales and development of its Indonesian coal bed methane assets. The offer is partially underwritten by a major shareholder and supports key milestones in the company’s transition to commercial production.

Aeris Environmental Ltd reports strong Q1 FY26 growth, expanding its Syncromesh smart building platform into new sectors and international markets while maintaining solid financial discipline.

Astron Limited has achieved major milestones for its Donald Rare Earth and Mineral Sands Project, including government recognition and conditional financing, setting the stage for a Final Investment Decision by year-end.

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Aspen Group has upgraded its FY26 pre-tax earnings guidance by 6%, driven by strong rental income growth and development profits amid Australia's acute housing shortage. The company also announces a strategic acquisition of a new Sydney headquarters.

Scout Security reported a significant 62% reduction in operating cash outflows for Q3 FY2025, while advancing a potential acquisition and partnership opportunities following CES. The company’s cash position remains tight, prompting ongoing capital raising efforts.

Scout Security reports a 52% jump in quarterly cash receipts and a 31% reduction in operating outflows, while advancing plans to acquire New York’s Roo Inc.

First Graphene Limited reveals significant progress in commercialising its PureGRAPH graphene technology, highlighting expanding global partnerships and a robust sales pipeline valued over A$10 million.

Streamplay Studio Limited reported a remarkable 201% surge in operating revenue for FY25, driven by its strategic acquisition of Noodlecake Studios and expansion into new markets. Despite a wider operating loss, the company achieved positive cash flow and profitability in the final quarter, signaling a promising turnaround.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Saferoads Holdings Limited reported a net profit of $4.35 million for FY2025, driven largely by a $5.27 million gain from the sale of its Road Safety Rental business. Continuing operations showed a modest loss amid a 14% revenue decline.

Atomo Diagnostics reported a 27% reduction in net loss to AUD 4.97 million for FY25, alongside a 7% revenue dip to AUD 3.79 million, driven by stronger margins and cost controls. The company also secured a significant US distribution contract through partner Lumos Diagnostics, positioning it for growth.